Bioventix (FRA:51B) Marketable Securities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:51B Bioventix PLC FRA:51B
67 GF Score
Price €16.70
GF Value €38.85
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bioventix Marketable Securities?

Bioventix FRA:51B -0.60% 67 Marketable Securities is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:51B with a GF Score™ of 67/100 and a GF Value™ of €38.85 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Bioventix's Marketable Securities for the quarter that ended in Dec. 2025 was €0.00 Mil.

Bioventix  (FRA:51B) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Bioventix Marketable Securities Related Terms

Bioventix Marketable Securities Historical Data

* Premium members only.

The historical data trend for Bioventix's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioventix Marketable Securities Chart

Bioventix Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bioventix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:51B
67GF Score
Bioventix PLC FRA:51B
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioventix Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Bioventix (FRA:51B) has a Marketable Securities of €0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bioventix and its competitors.
Is Bioventix's Marketable Securities too high?
Bioventix's current Marketable Securities is €0.00 Mil. Overall, Bioventix has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioventix's Marketable Securities compare to VRTX and REGN?
Bioventix's Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bioventix and its competitors. Bioventix's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Based on GuruFocus' analysis, Bioventix (FRA:51B) is currently considered Significantly Undervalued. The stock's GF Value™ is €38.85, compared to a current price of €16.70 — trading 57% below its estimated fair value. The current Marketable Securities is €0.00 Mil. Bioventix's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Bioventix (FRA:51B), the current Marketable Securities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioventix (FRA:51B) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventix stock appears to be undervalued. The current stock price of €16.70 is trading 57% below its estimated GF Value™ of €38.85. GuruFocus considers Bioventix to be Significantly Undervalued.

Key valuation signals for FRA:51B:

  • Marketable Securities: €0.00 Mil
  • GF Value™: €38.85 vs. price of €16.70 (57% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the FRA:51B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioventix Business Description

Other Exchanges BVXP:UK
Address 27-28 Eastcastle Street, London, GBR, W1W 8DH
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
67GF Score

Get the complete analysis for FRA:51B

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.70
Price
€38.85
GF Value